Regulatory reading desk / Renal-outcomes lens
Semaglutide is an FDA-approved GLP-1 peptide studied across kidney, heart, and weight-loss trials.
An independent reading of the registrational record and the regulatory status — the trials, the labeled indications, and the kidney-outcomes evidence, stated plainly and cited to source.
The short version
Semaglutide is a medicine that copies a natural gut hormone called GLP-1 — a signal the body releases after eating that tells you you are full and helps control blood sugar. It is approved by the U.S. Food and Drug Administration (the FDA, the agency that decides which medicines may be sold) for type 2 diabetes, long-term weight management, lowering the risk of heart attack and stroke in certain people, and, since 2025, a serious fatty-liver disease called MASH.
In large studies it lowered body weight, improved blood-sugar control, cut heart events, and — the focus of this page — slowed kidney decline in people with diabetes and kidney disease [6]. It is taken as a once-weekly shot or a once-daily tablet. The most common downside is stomach upset, mostly nausea early on. What people report — including the downsides — is on the effects page. Nothing here is medical advice, and nothing is for sale.
What the trial record shows
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a drug that activates the same receptor as the body's own GLP-1 hormone (a gut signal that prompts insulin release and reduces appetite). It is a 31-amino-acid peptide engineered for once-weekly dosing, and its evidence base is one of the largest in modern metabolic medicine.
In the SELECT trial of 17,604 adults with established cardiovascular disease and obesity but without diabetes, once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo (hazard ratio 0.80; 95% CI 0.72-0.90) [3]. In the STEP 1 weight-management trial, the same dose produced a mean body-weight change of -14.9% at 68 weeks versus -2.4% with placebo [1]. In SUSTAIN-6, the 0.5 and 1.0 mg doses reduced the cardiovascular composite in type 2 diabetes (HR 0.74; 95% CI 0.58-0.95) [2].
These are hard endpoints from large randomized trials, summarized here as a reading desk for the published record. Browse the full Semaglutide research for the study-by-study detail.
The renal-protection evidence
The kidney is where this site leads. In the FLOW trial of 3,533 adults with type 2 diabetes and chronic kidney disease, once-weekly semaglutide 1.0 mg reduced major kidney-disease events — kidney failure, a 50% or greater fall in kidney filtration (eGFR), or death from kidney or cardiovascular causes — by 24% versus placebo (HR 0.76; 95% CI 0.66-0.88) [6].
The finding matters because chronic kidney disease in diabetes has had few therapies that change its course. FLOW read out in 2024 and anchored a kidney-outcomes indication; a severity-stratified analysis reported that the cardiovascular benefit held across stages of kidney disease [12]. The structural basis is partly pharmacological: semaglutide's fatty-acid side chain binds tightly to the blood protein albumin, which protects the peptide from rapid kidney clearance and underpins its once-weekly schedule.
Approval status and the compounding history
Semaglutide is an approved prescription medicine, not an investigational compound. The FDA has cleared it across multiple indications and two formulations — a once-weekly subcutaneous injection and a once-daily oral tablet — covering type 2 diabetes, chronic weight management, cardiovascular risk reduction in established disease, and metabolic dysfunction-associated steatohepatitis (MASH) [9].
The regulatory record also includes a shortage chapter. During a federally declared shortage running from roughly 2022 to early 2025, compounding pharmacies were permitted to prepare semaglutide; that pathway was curtailed once the shortage was declared resolved in early 2025 [9]. The approved manufactured product and a compounded preparation are not the same thing under the law, and the published evidence summarized here describes the approved product. This is an editorial framing of the public record, not legal advice.
How to read this site
Every quantitative claim on this site is attributed to a named trial or review and listed on the Semaglutide references page with its DOI or PubMed link. The pages are organized by question rather than by marketing: what the molecule is, how it works, what the trials measured, what doses were studied, and what people actually report.
If you want the mechanism, start with how does semaglutide work. If you want the plain definition, start with what is semaglutide. For the human-experience layer — benefits and side effects people describe, clearly labeled as anecdotal — see Semaglutide effects. This is a reading desk, not a clinic, and not a place to obtain the medicine.